Institute for Clinical and Economic Review to Assess Treatments for Lupus Nephritis
August 11, 2020
August 11, 2020
BOSTON, Massachusetts, Aug. 11 -- The Institute for Clinical and Economic Review issued the following announcement on Aug. 10:
The Institute for Clinical and Economic Review (ICER) announced today that it plans to assess the comparative clinical effectiveness and value of voclosporin (Aurinia Pharmaceuticals, Inc.) and belimumab (BENLYSTA(R), GlaxoSmithKline) for the treatment of lupus nephritis. Voclosporin is seeking an initial approval for the treatment of lupus nephritis, and be . . .
The Institute for Clinical and Economic Review (ICER) announced today that it plans to assess the comparative clinical effectiveness and value of voclosporin (Aurinia Pharmaceuticals, Inc.) and belimumab (BENLYSTA(R), GlaxoSmithKline) for the treatment of lupus nephritis. Voclosporin is seeking an initial approval for the treatment of lupus nephritis, and be . . .